NCT00531063View on ClinicalTrials.gov

This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus

PHASE3CompletedINTERVENTIONAL
Enrollment

237

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

August 31, 2005

Conditions
Renal Transplantation
Interventions
DRUG

Everolimus (RAD001)

Trial Locations (1)

Unknown

Novartis, Basel

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY